--- title: "HTA, Health Technology Assessment | MedTech Terms" description: "Systematic evaluation of clinical and economic value of a health technology. Plain-English Reimbursement definition for MedTech teams, with examples and related" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/hta#term", "name": "Health Technology Assessment", "alternateName": "HTA", "description": "HTA bodies evaluate the clinical effectiveness, safety, and cost-effectiveness of medical technologies to inform coverage and pricing - NICE (UK), HAS (France), G-BA/IQWiG (Germany), CADTH (Canada), and the new EU Joint Clinical Assessment (JCA).", "url": "https://medtechterms.com/terms/hta", "termCode": "hta", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/hta#article", "headline": "HTA, Health Technology Assessment", "description": "Systematic evaluation of clinical and economic value of a health technology.", "url": "https://medtechterms.com/terms/hta", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/hta" }, "about": { "@id": "https://medtechterms.com/terms/hta#term" }, "articleSection": "Reimbursement", "inLanguage": "en", "keywords": "Health Technology Assessment, HTA, Reimbursement, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "INAHTA", "url": "https://www.inahta.org/", "publisher": { "@type": "Organization", "name": "INAHTA" } }, { "@type": "CreativeWork", "name": "AdvaMed - Payment & Coverage", "url": "https://www.advamed.org/our-work/", "publisher": { "@type": "Organization", "name": "AdvaMed" } }, { "@type": "CreativeWork", "name": "AMA CPT Resources", "url": "https://www.ama-assn.org/practice-management/cpt", "publisher": { "@type": "Organization", "name": "AMA" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/jca#term", "name": "Joint Clinical Assessment", "alternateName": "JCA", "url": "https://medtechterms.com/terms/jca" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/qaly#term", "name": "Quality-Adjusted Life Year", "alternateName": "QALY", "url": "https://medtechterms.com/terms/qaly" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Reimbursement", "item": "https://medtechterms.com/terms?cat=Reimbursement" }, { "@type": "ListItem", "position": 4, "name": "Health Technology Assessment", "item": "https://medtechterms.com/terms/hta" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/hta#faq", "mainEntity": [ { "@type": "Question", "name": "How does HTA differ from regulatory approval?", "acceptedAnswer": { "@type": "Answer", "text": "Regulatory approval (e.g., FDA clearance, CE Mark) focuses on ensuring a device is safe and effective for its intended use. HTA assesses the added value, cost-effectiveness, and real-world impact of a device to inform decisions about public funding and adoption." } }, { "@type": "Question", "name": "What kind of data is typically required for HTA?", "acceptedAnswer": { "@type": "Answer", "text": "HTA submissions often require comprehensive clinical data, health economic models, budget impact analyses, and evidence on patient-reported outcomes. This may include head-to-head comparisons with existing therapies and long-term efficacy data." } }, { "@type": "Question", "name": "How does EU HTA Regulation (2021/2282) impact MedTech companies?", "acceptedAnswer": { "@type": "Answer", "text": "The EU HTA Regulation introduces a framework for joint clinical assessments (JCAs) for certain medical devices and IVDs, aiming to streamline the process across Member States. Companies will submit clinical evidence once at the EU level, which will then be used by national HTA bodies for their national health economic evaluations and reimbursement decisions." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Reimbursement](/terms?cat=Reimbursement) 6. / 7. Health Technology Assessment [All terms](/terms) Reimbursement [Clinical Evidence](/ecosystems/clinical-evidence)[Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer)[Startup Lifecycle](/ecosystems/startup-lifecycle)HTA # Health Technology Assessment Systematic evaluation of clinical and economic value of a health technology. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition HTA bodies evaluate the clinical effectiveness, safety, and cost-effectiveness of medical technologies to inform coverage and pricing - NICE (UK), HAS (France), G-BA/IQWiG (Germany), CADTH (Canada), and the new EU [Joint Clinical Assessment](/terms/jca) (JCA). What the regulation says Health Technology Assessment (HTA) bodies like those referenced by the EU HTA Regulation (Regulation (EU) 2021/2282) play a crucial role in evaluating new and existing medical devices. These bodies consider clinical efficacy, safety, and cost effectiveness to inform national reimbursement and market access decisions. While not a direct regulatory approval [step](/terms/step), a positive HTA outcome is often a prerequisite for widespread adoption and reimbursement within a healthcare system. ## What this means in practice Outside the U.S., HTA decisions often gate market access. EU [JCA](/terms/jca) (effective 2025) creates a single clinical assessment across member states for high-risk devices and IVDs. ## Examples - A manufacturer of a novel orthopedic implant conducts a post-market clinical study to gather real-world effectiveness and cost utility data specifically for submission to Germany's G-BA. - A diagnostic company developing a new in vitro diagnostic (IVD) test includes health economic endpoints in its clinical trial design to satisfy anticipated requirements from national HTA agencies. - Before launching a new surgical robot in Canada, a MedTech company engages with CADTH to understand their evidence expectations for demonstrating value and securing reimbursement. Common pitfalls - • Misunderstanding HTA as a regulatory approval process, rather than a reimbursement and market access gate. - • Failing to consider HTA requirements early in product development, leading to late-stage data collection challenges. - • Underestimating the data requirements for HTA submissions, which often go beyond basic regulatory clinical evidence. - • Assuming that a device approved in one jurisdiction will automatically receive favorable HTA outcomes in others. - • Neglecting to engage with HTA bodies or experts during the clinical development planning phase. ## Frequently asked questions How does HTA differ from regulatory approval? Regulatory approval (e.g., FDA clearance, [CE Mark](/terms/ce-mark)) focuses on ensuring a device is [safe](/terms/safe-note) and effective for its [intended use](/terms/intended-use). HTA assesses the added value, cost-effectiveness, and real-world impact of a device to inform decisions about public funding and adoption. What kind of data is typically required for HTA? How does EU HTA Regulation (2021/2282) impact MedTech companies? ## Cross-references ### See also Closely related context worth reading. - [ Real-World Evidence(RWE) ](/terms/real-world-evidence) ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Reimbursement Joint Clinical Assessment(JCA) EU-wide clinical assessment of high-risk medical devices and IVDs. ](/terms/jca)[ Reimbursement Quality-Adjusted Life Year(QALY) Outcome metric combining length and quality of life used in HTA. ](/terms/qaly) ### Reimbursement & Market Access · From this learning path [ Reimbursement Budget Impact Model(BIM) Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon. Adjacent lesson ](/terms/budget-impact-model?from=reimbursement-and-market-access)[ Reimbursement Prior Authorization Payer requirement for approval before a service or device is covered. Adjacent lesson ](/terms/prior-authorization?from=reimbursement-and-market-access)[ Reimbursement CPT Codes(CPT) AMA-maintained codes that describe medical procedures and services. ](/terms/cpt-codes?from=reimbursement-and-market-access)[ Reimbursement Current Procedural Terminology Codes(CPT) AMA-maintained codes used to report medical procedures and services for billing. ](/terms/cpt?from=reimbursement-and-market-access) ### More in Reimbursement · Same category [ Reimbursement HCPCS Codes(HCPCS) CMS-maintained codes for products, supplies, and services not in CPT. ](/terms/hcpcs)[ Reimbursement ICD-10-CM / ICD-10-PCS Diagnosis (CM) and inpatient procedure (PCS) coding systems used in U.S. claims. ](/terms/icd-10) Cited by Where this term appears across MedTech Terms. Learning paths (1) - [Reimbursement & Market Access](/paths/reimbursement-and-market-access)Lesson 11 of 14 Ecosystems (3) - [Clinical Evidence](/ecosystems/clinical-evidence) - [Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) - [Startup Lifecycle](/ecosystems/startup-lifecycle) ## Mentioned in recent activity 1 entry PubMed (1) [Time Frame Analysis of Medical Device Approval, New Health Technology Assessment, and Reimbursement Decision-Making in Korea. ](https://pubmed.ncbi.nlm.nih.gov/42117148/) Journal of Korean medical science · 2026-05-11 ## Latest in MedTech [View all](/latest?term=hta) Recent regulatory actions, publications, and trials matched to this term. Updated daily. - PubMed 2026-05-11 [Time Frame Analysis of Medical Device Approval, New Health Technology Assessment, and Reimbursement Decision-Making in Korea. ](https://pubmed.ncbi.nlm.nih.gov/42117148/) Journal of Korean medical science ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 INAHTA· 1 AdvaMed· 1 AMA· 1 1. [1 INAHTA Verified INAHTA · inahta.org ](https://www.inahta.org/) 2. [2 AdvaMed - Payment & Coverage Verified AdvaMed · advamed.org ](https://www.advamed.org/our-work/) 3. [3 AMA CPT Resources Verified AMA · ama-assn.org ](https://www.ama-assn.org/practice-management/cpt) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Need cybersecurity expertise on a connected-device launch? Blue Goat Cyber helps MedTech teams ship connected products that hospital security teams will actually procure. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Reimbursement Acronym HTA Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=hta) Learn in 60 seconds Card Lesson Quiz Systematic evaluation of clinical and economic value of a health technology. - · Outside the U.S., HTA decisions often gate market access. - · EU JCA (effective 2025) creates a single clinical assessment across member states for high-risk devices and IVDs. Remember this Watch out: Misunderstanding HTA as a regulatory approval process, rather than a reimbursement and market access gate. Related terms - [Joint Clinical Assessment(JCA) ](/terms/jca) - [Quality-Adjusted Life Year(QALY) ](/terms/qaly) You may also need Auto-suggested from Reimbursement and shared keywords. - [Health Economics and Outcomes Research(HEOR) ](/terms/heor) - [Incremental Cost-Effectiveness Ratio(ICER) ](/terms/icer) - [Budget Impact Model(BIM) ](/terms/budget-impact-model) - [RWE for Reimbursement ](/terms/real-world-evidence-reimbursement) - [Value Analysis Committee(VAC) ](/terms/vac) - [Transitional Coverage for Emerging Technologies(TCET) ](/terms/tcet) [All Reimbursement terms](/terms?cat=Reimbursement) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)